相关临床试验
1179
90 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
终止
114
9.7%
招募中
141
12.0%
暂停
7
0.6%
撤回
47
4.0%
进行中（未招募）
44
3.7%
Unknown
5
0.4%
已完成
775
65.7%
Enrolling By Invitation
12
1.0%
尚未招募
34
2.9%
暂无批准数据
- A comprehensive review of over 350 studies finds that dietary protein restriction can improve metabolic health, reduce cellular damage, and extend lifespan across diverse organisms. - The hormone FGF21 emerges as a central mediator, rising during low protein intake to boost energy expenditure, improve glycemic control, and lower systemic inflammation. - Specific amino acids—methionine, isoleucine, and valine—are identified as key drivers of growth signaling pathways that, when overconsumed, may accelerate age-related metabolic decline. - Researchers emphasize that protein recommendations should be personalized based on physical activity levels, as exercise may protect against the negative effects of high-protein diets.
- A review of over 350 papers published in Cell Press Blue finds that consuming less protein may improve metabolism, reduce cellular damage, and extend lifespan, particularly in sedentary individuals. - The hormone FGF21, which rises when protein intake is low, appears to increase energy expenditure, improve blood sugar control, and reduce inflammation. - Restricting specific amino acids such as methionine, isoleucine, and valine may drive many of the observed anti-aging benefits. - Researchers call for personalized protein recommendations based on physical activity levels, not just age, noting that exercise may protect against negative effects of high-protein diets.
- Researchers used optogenetic stimulation to induce NREM sleep-like neural activity in localized brain regions of awake, sleep-deprived mice, effectively mimicking the restorative effects of sleep. - The rhythmic on-and-off firing pattern, not overall reduction in neuronal activity, was identified as the critical mechanism driving sleep's restorative benefits for memory consolidation. - Sleep-deprived mice receiving bilateral stimulation performed on par with well-rested controls in tactile memory tests, while non-stimulated sleep-deprived mice showed significant impairment. - The findings open translational avenues for non-invasive transcranial stimulation technologies in humans to potentially prevent and treat cognitive decline.
- FUJIFILM Cellular Dynamics opened a new 175,000-square-foot headquarters and iPSC manufacturing facility in Madison, Wisconsin, as part of a $200 million strategic investment by Fujifilm. - The facility is expected to quadruple the company's manufacturing capacity for iPSC-based research products and expand capabilities for next-generation cell therapy development. - The expansion addresses growing demand from pharmaceutical companies for new approach methods (NAMs) in drug discovery as regulatory guidance shifts away from animal testing. - The facility integrates state-of-the-art capabilities including cell culture manufacturing laboratories, process development laboratories, and a center of excellence for gene editing.
- NeuraWorx Medical Technology closed an oversubscribed seed funding round led by Nexus NeuroTech Ventures to advance its first-in-class Cerebrovascular Pacing System for central nervous system disorders. - The company is targeting cerebrovascular and glymphatic dysfunction, which is increasingly implicated in neurodegenerative and neuropsychiatric diseases. - The funding will enable NeuraWorx to scale its team in neuroscience, clinical development, and regulatory affairs to accelerate clinical and regulatory programs. - The bioelectronic platform is designed to restore cerebrovascular and glymphatic function by enhancing brain fluid dynamics.
- SK Biopharmaceuticals has acquired exclusive worldwide rights to WT-7695, a preclinical radiopharmaceutical candidate targeting carbonic anhydrase IX (CA9) from the Wisconsin Alumni Research Foundation. - WT-7695 demonstrated strong binding affinity, tumor selectivity, prolonged tumor retention, and complete tumor growth inhibition in preclinical studies targeting clear cell renal cell carcinoma and other solid tumors. - This represents SK Biopharmaceuticals' second radiopharmaceutical asset following SKL35501 in 2024, as the company builds an integrated value chain including partnerships with TerraPower and PanTera for radioisotope sourcing. - CA9 is highly expressed in clear cell renal cell carcinoma and other solid tumors like pancreatic and colorectal cancers while showing limited expression in normal tissues.
- University of Wisconsin-Madison researchers have developed personalized cancer vaccines using pyroptotic vesicles, tiny sacs from dying cancer cells, that significantly extended survival in mouse models of triple-negative breast cancer and melanoma. - The engineered vesicles contain tumor-specific antigens and are embedded in hydrogels implanted at surgical sites, creating localized immune responses that reduce systemic side effects compared to traditional cancer vaccines. - Mice receiving the highest doses of the experimental treatment remained cancer-free throughout the study, with researchers demonstrating potential applications for other recurring cancers like pancreatic cancer and glioblastoma. - The approach represents the first demonstration of pyroptotic vesicles' effectiveness in preventing cancer recurrence, with the research team being among the first to identify these cellular byproducts.
- Seer's new Proteograph ONE Assay and SP200 Automation Instrument can process over 1,000 samples per week, doubling throughput while reducing per-sample costs by approximately 60% compared to 2021. - Korea University will conduct the first large-scale plasma proteomics study of its kind, analyzing 20,000 samples from cancer patients and healthy controls to develop AI-driven diagnostics for early-onset cancers in young adults. - The three-year study, funded by Korea's K-Health MIRAE initiative, aims to identify novel blood-based biomarkers for cancer detection in patients in their 20s and 30s using samples from leading Korean cancer institutions. - The new workflow identifies up to 10 times more proteins than conventional mass spectrometry methods and completes 80-sample batches in under 5 hours of automated runtime.
- Archeus Technologies and Wisconsin Alumni Research Foundation announced a strategic collaboration to advance ART-101, a next-generation PSMA-targeting radiopharmaceutical, into clinical development with Phase 1 trials planned for 2025. - Preclinical studies demonstrate that ART-101 shows significantly higher tumor uptake and retention compared to FDA-approved Pluvicto, along with superior pharmacokinetics and improved normal tissue toxicity profiles. - The novel receptor-based targeting molecule is compatible with multiple therapeutic isotopes including actinium-225, lutetium-177, and terbium-161, potentially offering improved outcomes for prostate cancer patients. - ART-101 was developed at UW-Madison's Advanced Radiotheranostics Lab with support from WARF Accelerator and represents a promising advancement in theranostics for challenging-to-treat cancers.
- Scientists have developed a revolutionary bioprinter that uses ultrasound technology to create tissues, biosensors, and medication depots deep within the body without requiring surgical intervention. - The non-invasive technique represents a significant advancement in regenerative medicine, potentially transforming treatment approaches for tissue damage and drug delivery systems. - This technology builds upon previous methods like infrared light-based implant shaping, but offers deeper tissue penetration capabilities, according to experts including Xiao Kuang from the University of Wisconsin-Madison.
